Our partnerships with the pharmaceutical industry
Our partnerships with pharmaceutical companies allow us to deliver vital work supporting people affected by blood cancer.
The support we received in FY23 is detailed below. You can also find reports from the last three years available to download.
(Unless otherwise stated, these companies played no part in the organisation, design, or content of any of the work listed).
For more information on how and why we work with the industry, read our Policy on working with pharma.
Our 2023 report
Janssen funded £25,000 worth of research undertaken by UCL in order to reduce delays to diagnosis of blood cancer.
£45,380 worth of funding was directed towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.
Takeda directed £45,380 worth of funding towards the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.
£120,000 went towards supporting the Covid-19 Vaccine Research Collaborative. Another £35,000 worth of funding was directed at the Blood Cancer Action Plan - a national report that will identify and make meaningful, realistic recommendations for change to improve survival of blood cancer patients.
Roche funded £25,000 towards health information transformation.
£15,000 went towards supporting our Clinical Trials Support Service.
AstraZeneca provided £15,000 to help fund a fixed-term Covid Policy Offer job role.
£5,000 went towards supporting our Clinical Trials Support Service.
GSK funded £20,000 worth of research based on data from Covid treatment centres.
Get in touch with the Corporate Partnerships Team
Get in touch